Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Kisqali - eviQ / Cancer Institute NSW
Product / population
eviQ protocol 3379, oral ribociclib for metastatic breast cancer.
Renal method
Indexed eGFR in mL/min/1.73 m2.
Source revision
Kidney modification updated October 8, 2025; protocol change log includes October 30, 2026.
All record notes are retained here, including notes about sources not selected in this review.
Kisqali - product and source limitations
The inequality in the U.S. renal subsection is awkwardly rendered. Verify the named severity category in the label. eviQ provides a separate indexed-eGFR instruction for its metastatic breast cancer regimen.
What to reconcile: The inequality in the U.S. renal subsection is awkwardly rendered. Verify the named severity category in the label. eviQ provides a separate indexed-eGFR instruction for its metastatic breast cancer regimen.
Protocol 3379, Dose modifications, Kidney dosing recommendations and treatment schedule
In its metastatic breast cancer protocol, eviQ retains the regimen at indexed eGFR 30 or above. Below 30 it advises a cautious 200 mg starting dose on treatment days because evidence is limited. Retain the protocol cycle and its ECG, electrolyte and blood-count monitoring.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
